** Shares of Mesoblast rise as much as 46% to A$2.890, their highest since Dec. 16, 2020
** Stock posts its biggest intraday percentage rise since April 2
** Drug developer says U.S. Food and Drug Administration approved co's cell therapy for graft-versus-host disease
** About 28.1 mln shares change hands, compared with the 30-day average volume of around 6.3 mln
** Stock up over 825% YTD, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。